Clinical TrialID 6136
Perillyl Alcohol in Treating Patients With Refractory Cancer
NCT00002862
Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 6136
- Evidence Id
- 6136
- Core Evidence Id
- 6136
- Source Clinical Trial Id
- 6122
- Herb2 Clinical Trial Id
- HBCT006122
- Nct Id
- NCT00002862
- Title
- Perillyl Alcohol in Treating Patients With Refractory Cancer
- Status
- Completed
- Phase
- Phase 1
- Study Result
- No
- Study Condition
- Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific
- Study Type
- Interventional
- Study Design
- Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
- Intervention
- DRUG: perillyl alcohol
- Intervention Allocation
- Intervention Model
- Single_Group
- Intervention Mask
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 25
- Outcome Measure
- Sponsor Collaborator
- National Cancer Institute (NCI)
- Funded By
- NIH
- Location
- Yale Comprehensive Cancer Center, New Haven, Connecticut, 06520-8028, United States
- Other Id
- CDR0000065133|YALE-HIC-8895|NCI-T96-0064D
- Start Date
- 1996-10
- Primary Completion Date
- 2001-04
- Completion Date
- First Posted
- 2004-07-19
- Results First Posted
- Last Update Posted
- 2013-02-11
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT00002862
- Title Cn
- Title En
- Perillyl Alcohol in Treating Patients With Refractory Cancer
- Bilingual Status
- semi_complete